A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.

Eli Lilly (LLY) stock in focus as eczema therapy Ebglyss lead to complete skin clearance in 50% of subjects in a long-term extension study. Read more here.

Lilly said it expects to reveal the specific locations for the sites later this year, adding that it is negotiating with several states. The company would not confirm whether Indiana is among them. The drugmaker said the move will more than double its U.

The Indianapolis-based pharmaceutical company announced plans for four new manufacturing sites, but has not decided where they will go.

Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

The push to onshore manufacturing was already underway at Lilly, which has been investing heavily to boost production capacity for Zepbound and Mounjaro.

Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .

Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine.

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

In addition to "reshoring" the production of key ingredients used to make some of their drugs, Lilly said it will create 3,000 jobs at the sites.